Policy
Sanofi Targets €25B Dupixent Goal and Expands M&A Hunt
On Sunday, September 20, 2026, Sanofi (NASDAQ: SNY) raised its 2030 Dupixent sales target to €25 billion while aggressively expanding its M&A strategy ahead of early 2030s patent expirations. Executive Vice President Manuela Buxo outlined plans for both larger transformative deals and smaller tuck-in transactions.
oil gasutilitiesclean energy
For , monitor how management allocates capital toward potential large-scale or multi-target M&A transactions to sustain growth beyond the upcoming Dupixent patent expiration.
